Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04800614 · ClinicalTrials.gov registry record · Phase 1

A Study to Explore the Effect of Food Before a Single Dose of Sitravatinib

A Phase 1 study of Healthy Adults, sponsored by Mirati Therapeutics.

Completed
Registry status
Phase 1
Development phase
36
Enrollment target
1
Study location

NCT04800614 is a Phase 1 study of Healthy Adults that has completed, run by Mirati Therapeutics. The registered enrollment target is 36 participants, below the 85-participant average among 33 other Healthy Adults trials with a reported enrollment target (58% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04800614, a Phase 1 study of Healthy Adults, has completed, sponsored by Mirati Therapeutics.

COMPLETED
Registry status
Phase 1
Development phase
36 participants
Enrollment target
1
Study location

Study Summary

An Open-label, Randomized, Three-period, Crossover Study of the Effect of Food on the Pharmacokinetics of a Single Oral Dose of Sitravatinib in Healthy Adult Subjects

Conditions Studied

Interventions

  • DRUG sitravatinib

Study Locations (1)

Texas

  • Covance Clinical Research Unit, Inc. - Dallas

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2021-03-15
Est. Completion 2022-03-28
Phase Phase 1

Sponsor

Mirati Therapeutics

49 total trials

What the Registry Record Tells You About NCT04800614

The ClinicalTrials.gov registry entry for NCT04800614 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 85-participant average among 33 other Healthy Adults trials with a reported enrollment target (58% lower). The listed sponsor is Mirati Therapeutics, which has 49 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy Adults appearing as the primary indexed condition, and to 1 intervention - of which sitravatinib is the first listed.

NCT04800614 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT04800614 about?

NCT04800614 is a clinical study titled "A Study to Explore the Effect of Food Before a Single Dose of Sitravatinib". An Open-label, Randomized, Three-period, Crossover Study of the Effect of Food on the Pharmacokinetics of a Single Oral Dose of Sitravatinib in Healthy Adult Subjects

What is the current status of trial NCT04800614?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2021-03-15. Estimated completion is 2022-03-28.

What conditions does trial NCT04800614 study?

This clinical trial studies the following conditions: Healthy Adults.

What interventions are being tested in trial NCT04800614?

The interventions under investigation include: sitravatinib (DRUG).

Who is sponsoring clinical trial NCT04800614?

This trial is sponsored by Mirati Therapeutics, which has 49 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04800614 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Adults

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.